mRNA Flu Vaccine Demonstrates 100% Effectiveness in New Trial

A human-challenge randomized controlled trial, published last week in NEJM Evidence, finds that an mRNA (modRNA) influenza vaccine is 100% effective against both symptomatic and febrile flu, compared with 85% and 100% with the conventional quadrivalent (four-strain) influenza vaccine (QIV). Source

The Study: A Head-to-Head Comparison

A team led by scientists from vaccine developer Pfizer conducted the phase 2a, double-blind trial by randomly assigning healthy adults aged 18-49 to receive either the mRNA influenza vaccine or the standard QIV.the study involved intentionally exposing participants to influenza A viruses. This “human challenge” approach allows researchers to directly measure vaccine effectiveness in a controlled habitat.

How the Trial Worked

Participants were randomized to receive either the mRNA vaccine or the QIV. after vaccination, all participants were deliberately infected with a matched strain of influenza A virus. Researchers then monitored participants for the growth of symptomatic illness (defined as fever and cough) and measured viral load.

Key Findings: 100% Protection with mRNA Vaccine

The results showed a significant difference in protection between the two vaccines:

• mRNA Vaccine: 100% effective against symptomatic influenza and 100% effective against febrile influenza.
• QIV Vaccine: 85% effective against symptomatic influenza and 100% effective against febrile influenza.

The mRNA vaccine also demonstrated a faster onset of protection compared to the QIV. Source

What is an mRNA Vaccine?

mRNA vaccines work by delivering genetic instructions (mRNA) to your cells, telling them to produce a harmless piece of a virus. This triggers an immune response, preparing your body to fight off the real virus if you encounter it. Unlike customary vaccines, mRNA vaccines do not contain a weakened or inactivated virus.

Implications for Future Flu Vaccines

These findings suggest that mRNA technology holds significant promise for developing more effective influenza vaccines. The 100% effectiveness against symptomatic illness observed in this trial is especially encouraging. The ability to rapidly design and manufacture mRNA vaccines also offers a potential advantage in responding to emerging influenza strains and future pandemics.

Why is this crucial?

Influenza causes significant morbidity and mortality worldwide. A more effective vaccine could substantially reduce the burden of this disease. The speed with which mRNA vaccines can be updated to match evolving viral strains is a crucial advantage over traditional vaccine manufacturing processes.

FAQ

What is a human challenge trial?

A human challenge trial involves deliberately infecting participants with a pathogen (like a virus) after they have been vaccinated. This allows researchers to directly assess vaccine effectiveness in a controlled setting.

Is the mRNA flu vaccine currently available?

As of November 26, 2025, the mRNA flu vaccine is still in development and is not yet widely available. Further clinical trials are needed before it can be approved for public use.

How does the mRNA flu vaccine compare to other flu vaccines?

This trial demonstrates superior effectiveness against symptomatic influenza compared to the standard quadrivalent influenza vaccine (QIV).

Publication Date: 2025/11/26 08:08:37